title: Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
abstract: We intended to identify the prognostic factors and the results of interventions on patients with liver metastatic midgut carcinoids. Five institutions that are part of United Kingdom and Ireland neuroendocrine tumour (NET) group took part in this study. Patients were included if they had histology proven NET of midgut origin and liver metastases at the time of the study. Clinical and biochemical data were collected retrospectively from hospital charts, pathology reports, radiology reports and biochemistry records for each patient. Three hundred and sixty patients were included in the study. The median survival from date of diagnosis was 7.69 years (confidence interval (CI) 6.40-8.99) and 5.95 years (CI 5.02-6.88) from date of diagnosis of liver metastases. On univariate analysis, increasing age at diagnosis, increasing urinary hydroxyindole acetic acid levels, increasing plasma chromogranin A levels, high Ki67, high tumour volume and treatment with chemotherapy were identified as factors associated with a significantly poorer outcome. Resection of liver metastases, resection of small bowel primary, treatment with somatostatin analogue therapy and treatment with peptide receptor therapy were associated with improved prognosis. Multivariate analysis revealed that age at diagnosis (P=0.014), Ki67 level (P=0.039) and resection of primary (P=0.015) were independent predictors of survival. This is the largest study to our knowledge looking specifically at the prognosis and clinical course of patients with liver metastatic midgut NETs. For the first time, we have shown that Ki67 and resection of primary are independent predictors of survival for this group of patients.
authors.affiliation: Basingstoke and North Hampshire Foundation Trust, Basingstoke, UK.
authors.forename: A
authors.initials: A
authors.lastname: Ahmed
authors.forename: G
authors.initials: G
authors.lastname: Turner
authors.forename: B
authors.initials: B
authors.lastname: King
authors.forename: L
authors.initials: L
authors.lastname: Jones
authors.forename: D
authors.initials: D
authors.lastname: Culliford
authors.forename: D
authors.initials: D
authors.lastname: McCance
authors.forename: J
authors.initials: J
authors.lastname: Ardill
authors.forename: B T
authors.initials: BT
authors.lastname: Johnston
authors.forename: G
authors.initials: G
authors.lastname: Poston
authors.forename: M
authors.initials: M
authors.lastname: Rees
authors.forename: M
authors.initials: M
authors.lastname: Buxton-Thomas
authors.forename: M
authors.initials: M
authors.lastname: Caplin
authors.forename: J K
authors.initials: JK
authors.lastname: Ramage
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002423:Cause of Death; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007414:Intestinal Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D007494:Ireland; D008113:Liver Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000556:secondary* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom; D055815:Young Adult